BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251117
DTEND;VALUE=DATE:20251120
DTSTAMP:20260515T035144
CREATED:20250905T113422Z
LAST-MODIFIED:20250905T113422Z
UID:41887-1763337600-1763596799@www.pharmajournalist.com
SUMMARY:9th Antifibrotic Drug Development Summit
DESCRIPTION:2025 has seen a wave of positive anti-fibrosis advances. From Agomab’s Phase 2a results in fibrostenosing Crohn’s\, Boehringer’s Phase 3 IPF data\, Stanford’s TGF-β work in cardiovascular fibrosis\, to over $3B in deals from Lilly\, GSK\, and others\, it’s clear the antifibrotic drug development landscape is undergoing a seismic shift. \nThat’s why this year’s Antifibrotic Drug Development Summit is THE place to be this November.  Learn from the industry’s premier experts at the forefront of fibrosis research\, gain unmissable cross-fibrosis insights\, and make unmatched connections with 80+ industry leaders from Pfizer\, Eli Lilly\, Novartis\, Takeda and more! \nAccess this year’s incredible lineup of speakers \nJoin us this year to: \n\nUnlock novel targets with advances in single-cell and spatial omics\, immune-stromal interactions\, and cross-tissue mechanisms\, featuring insights from Harvard Medical School\, Gilead Sciences\, and AdaptVac\nStrengthen translational confidence with precision-cut tissue slices\, 3D models\, and AI-driven biomarker strategies to bridge the gap between preclinical promise and clinical success\nDesign winning clinical programs with lessons from recent Phase 2 data\, including Resmetirom’s approval for MASH fibrosis and emerging IPF signals from GRI Bio and Redx Pharma\nNavigate the evolving landscape with expert perspectives on combination therapies\, GLP-1 competition\, and investor priorities to position your pipeline for partnerships and approvals\n\nDon’t miss out – invite your colleagues to join you and take advantage of our early bird rates and group savings! \nSecure my spot
URL:http://www.pharmajournalist.com/event/9th-antifibrotic-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T035144
CREATED:20250731T102550Z
LAST-MODIFIED:20250731T102550Z
UID:41600-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:Model-Informed Drug Development Summit
DESCRIPTION:With the release of the draft ICH M15 guidelines and the FDA’s move to phase out animal testing\, regulatory change is accelerating\, solidifying Model-Informed Drug Development (MIDD) as a critical\, non-negotiable tool in the drug development process. \nThe Model-Informed Drug Development Summit is the first and only industry-focused\, 3-day strategic meeting dedicated to exploring how MIDD is transforming decision-making and driving drug development success. This is your opportunity to benchmark against industry leaders\, refine your strategy\, and future-proof your development approach. \nJoin senior experts in pharmacometrics\, clinical pharmacology\, PK/PD\, and modeling from leading organizations including Pfizer\, Third Rock Ventures\, Johnson & Johnson\, AbbVie\, and more\, as they uncover how MIDD is being used to: \n\nSelect better candidates earlier in development\nStreamline or eliminate clinical trial phases\nPersonalize and optimize trial designs\nBuild stronger\, data-driven regulatory submissions\n\nWhy Attend? \n\nUnlock real-world case studies showing how MIDD accelerates timelines\, cuts costs\, and improves outcomes\nGain insight into how peers are implementing MIDD from discovery through to regulatory approval\nCollaborate with cross-functional teams to exchange strategies and overcome shared challenges\n\nWith exclusive insights into ICH M15\, practical applications across diverse therapeutic areas\, and proven examples of success\, this summit is your one-stop shop for unleashing the full potential of MIDD. \nLearn more here: https://ter.li/unljt8
URL:http://www.pharmajournalist.com/event/model-informed-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T035144
CREATED:20250731T103150Z
LAST-MODIFIED:20250731T103150Z
UID:41605-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:3rd LNP Characterization & Analytical Development Summit
DESCRIPTION:3rd LNP Characterization & Analytical Development Summit\nDe-Risk Regulatory Submissions Through Smarter LNP Characterization \nCurated in collaboration with leading analytical scientists and key LNP stakeholders\, the 3rd LNP Characterization & Analytical Development Summit returns with new data\, fresh insights\, and an expanded speaker lineup. As the definitive forum for LNP analytics and characterization\, this summit is your go-to platform for driving the development of safe\, effective\, and high-quality LNP-based drug products. \nThis highly focused\, three-day agenda will equip analytical experts with the technical insights needed to: \n\nAccelerate development timelines\nBridge critical analytical gaps\nStreamline regulatory submissions for faster approval\n\nJoin over 90 industry leaders in analytics\, characterization\, assays\, and CMC from organizations including Pfizer\, Novo Nordisk\, Prime Medicine\, Tessera Therapeutics\, GSK\, Sanofi\, and more. \nKey Benefits of Attending: \n\nGain deep technical knowledge on cutting-edge LNP analytics\nDiscover strategies to overcome common characterization challenges\nAlign on regulatory expectations to support faster\, smoother submissions\nNetwork with peers tackling the same development and regulatory hurdles\n\nWith data-driven presentations and expert-led discussions\, this is your opportunity to help define and implement robust analytical strategies that support the rapid development and approval of next-generation genomic medicines. \nLearn more here: https://ter.li/ympfix
URL:http://www.pharmajournalist.com/event/3rd-lnp-characterization-analytical-development-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T035144
CREATED:20250829T120700Z
LAST-MODIFIED:20250829T120700Z
UID:41824-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:7th Myeloid-Directed Therapies Summit
DESCRIPTION:The Only Industry-Dedicated Summit for Advancing Myeloid Cell Therapies in Oncology\, Inflammation and Beyond… \nUniting leading experts from pharma\, biotech\, and academia\, the 7th Myeloid-Directed Therapies Summit is the definitive event for anyone developing macrophage- and neutrophil-targeted therapies. As the field pushes beyond T-cells\, this forum dives into myeloid reprogramming\, cell state heterogeneity\, and translational challenges to unlock next-generation immune modulation. \nWith breakthrough insights from Eli Lilly\, AbbVie\, Pfizer\, AstraZeneca\, and Faron Pharmaceuticals\, and cutting-edge academic labs\, this is your opportunity to explore clinical case studies\, dissect failed monotherapy lessons\, and gain clarity on patient stratification\, trial design\, and combination strategies. \nLearn more: https://ter.li/by8e82
URL:http://www.pharmajournalist.com/event/7th-myeloid-directed-therapies-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T035144
CREATED:20250912T125210Z
LAST-MODIFIED:20250912T130631Z
UID:41941-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:9th Dermatology Drug Development Summit
DESCRIPTION:The 9th Dermatology Drug Development Summit is the definitive industry-led forum bringing together a driven community of experts pioneering innovative drug discovery and clinical strategies to improve long-term outcomes for patients with immuno-inflammatory disease. With disease heterogeneity and biomarker discovery fueling a new wave of research\, and clinical pipelines facing intensifying competition\, the need to develop differentiated\, novel candidates has never been more critical. \nAs the field accelerates with clinical and commercial momentum\, highlighted by Sanofi’s continued success with Dupixent\, Corvus’ promising Phase 1 data on Soquelitinib\, and landmark deals such as Gilead’s $1.7B inflammation partnership with LEO Pharma – this summit provides an essential platform to stay ahead of the curve. Returning this November\, the meeting unites 120+ leading experts from pharma\, biotech\, and academia\, all dedicated to overcoming the most pressing R&D bottlenecks in dermatology drug development. \nAttendees will gain insights into the latest preclinical and clinical findings across both rare and common conditions\, including atopic dermatitis\, psoriasis\, hidradenitis suppurativa\, vitiligo\, pemphigus nodularis\, bullous pemphigoid\, and alopecia areata. Sessions will explore the complexity of disease heterogeneity\, emerging mechanisms of action\, safety considerations\, and the evolving regulatory landscape. With contributions from thought leaders at AbbVie\, Sanofi\, Takeda\, Incyte\, Merck\, and other trailblazing organizations\, discussions will span discovery\, preclinical\, translational\, clinical\, and medical affairs perspectives. \nThe program also offers a forward-looking exploration of the modalities reshaping dermatology pipelines\, from bispecifics and biologics to oligonucleotides and beyond. By combining cutting-edge science with real-world clinical and strategic insights\, the 9th Dermatology Drug Development Summit equips participants with the tools to accelerate innovation\, navigate increasing competition\, and ultimately deliver therapies that transform patient quality of life. \nIf you’d like to learn more about the summit\, download the event guide or get in touch!
URL:http://www.pharmajournalist.com/event/9th-dermatology-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251119
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T035144
CREATED:20250829T114330Z
LAST-MODIFIED:20250829T114330Z
UID:41806-1763510400-1763683199@www.pharmajournalist.com
SUMMARY:3rd Donor Selection & Cell Source Summit
DESCRIPTION:Returning for its third year\, the Donor Selection & Cell Source Summit is the only industry-dedicated forum focused exclusively on the strategic and scientific challenges of donor selection and cell sourcing for allogeneic therapies. \nThis summit brings together leading minds from biopharma\, blood banks\, apheresis providers\, and cell therapy innovators to address one of the most critical bottlenecks in the development of scalable\, off-the-shelf treatments. \nWith over 600 allogeneic clinical trials currently underway\, the pressure to secure high-quality\, consistent donor-derived starting material has never been greater. This summit provides a unique opportunity to explore how smarter donor screening\, recruitment\, and retention strategies can directly impact product quality\, manufacturing scalability\, and clinical success. \nAttendees will gain actionable insights into: \n\nDonor testing and screening protocols that improve product safety and consistency\nRetention strategies to build reliable donor pools\nCryobiology and supply chain innovations that enhance cell viability and streamline logistics\nAnalytical development and quality control for robust characterization of starting material\n\nSee what other insights you can walk-away with in the program: https://ter.li/c2h7ym \nThe summit features expert speakers from leading organizations including Bristol Myers Squibb\, Genentech\, Allogene Therapeutics\, ImmuneBridge\, NKILT\, Luminary Therapeutics\, and many more offering a cross-functional perspective on how donor and source decisions shape the future of cell therapy. \nUnlike broader cell therapy conferences\, this event zeroes in on the upstream decisions that define downstream success. Whether you’re optimizing donor engagement\, navigating regulatory complexities\, or refining your sourcing strategy\, the Donor Selection & Cell Source Summit provides the tools and connections to move your program forward. \nExpect two days of deep scientific exchange\, strategic discussion\, and collaborative problem-solving in an intimate setting designed to foster meaningful dialogue. If you’re working to unlock the full potential of allogeneic therapies\, this is the one event you can’t afford to miss. \nFor more information on the summit\, view the program: https://ter.li/dc18d1
URL:http://www.pharmajournalist.com/event/3rd-donor-selection-cell-source-summit/
LOCATION:Westin Bayview San Diego\, 1051 Columbia St\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR